Germany, Canada and the Netherlands suspend use of AstraZeneca after cases of thrombosis and deaths

Germany, Canada and now the Netherlands, on Friday (2), decided that people under the age of 60 should not receive the vaccine against Covid-19 developed by AstraZeneca in partnership with the University of Oxford.

The justification of the three countries is the clotting problems that are appearing in people who have recently received the vaccine.

In the Netherlands, there were five reports of women aged 25 to 65 who developed thrombosis after being vaccinated in the country, one of whom died of extensive pulmonary embolism ten days after receiving the AstraZeneca immunizer.

In Germany, there were 31 cases of thrombosis and nine fatal victims, two men aged 36 and 57 years old and seven women aged between 20 and 63 years old. Canada, for its part, did not report any cases of blood clotting problems after applying the Oxford vaccine, but was concerned about the recurrence in other countries.

Both the World Health Organization (WHO) and the European Medicines Agency (EMA) stated that there is no direct link between the vaccine and the cases of thrombosis reported in several countries.

The UK Medicines and Health Products Regulatory Agency said the risks are “very small”, as 18.1 million people received the vaccine in the country. “The risk and benefit decision that people have when invited to receive the vaccine is simple: receiving the vaccine is by far the safest option,” said Adam Finn, a member of the Joint Vaccination and Immunization Committee.

With information from Jovem Pan


Get the latest news delivered to your inbox

Follow us on social media networks

PREV Fiat Strada surpasses Chevrolet Onix in accumulated sales
NEXT Economists now predict recession for second wave of Covid and slow vaccination | Economy